ReviewWorld journal of gastroenterology2012
Kidneys in chronic liver diseases.
Review in World journal of gastroenterology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Efficacy of combination therapy with natriuretic and aquaretic drugs in cirrhotic ascites patients: A randomized study.World journal of gastroenterology · 2017Trial
- Baseline Chronic Kidney Disease and Ischemic Method of Partial Nephrectomy Are Important Factors for the Short- and Long-Term Deterioration in Renal Function for Renal Cell Carcinoma Staged T1-T2: A Retrospective Single Center Study.BioMed research international · 2016Trial
- Elevated Fatty Acid Binding Protein 4 (FABP4) Associated With Liver Damage and Kidney Complications in Thalassemia Patients.BioMed research international · 2026Article
- Acute Compartment Syndrome and Intra-Abdominal Hypertension, Decompression, Current Pharmacotherapy, and Stable Gastric Pentadecapeptide BPC 157 Solution.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Characteristics of acute kidney injury and its impact on outcome in patients with acute-on-chronic liver failure.BMC gastroenterology · 2022Article
- Renal-function change after transjugular intra-hepatic portosystemic shunt placement and its relationship with survival: a single-center experience.Gastroenterology report · 2021Article
- Cardiac and renal effects of liver cirrhosis in a growing animal model.Acta cirurgica brasileira · 2021Article
- Peritoneal Dialysis in a Patient with Acute Kidney Injury, Thrombocytopenia, Urosepsis, and Liver Cirrhosis: A Case Report.The American journal of case reports · 2020Article
- Urinary neutrophil gelatinase-associated lipocalin determines short-term mortality and type of acute kidney injury in cirrhosis.JGH open : an open access journal of gastroenterology and hepatology · 2020Article
- Article
- Factors associated with renal dysfunction in hepatitis C-related cirrhosis and its correlation with Child-Pugh score.BMJ open gastroenterology · 2019Article
- Acute kidney injury in children with chronic liver disease.Pediatric nephrology (Berlin, Germany) · 2019Review
- Advances in the Diagnosis and Treatment of Acute Kidney Injury in Cirrhosis Patients.BioMed research international · 2017Review
- Outcomes of liver transplantation in patients with hepatorenal syndrome.World journal of hepatology · 2016Review
- Low Serum Lysosomal Acid Lipase Activity Correlates with Advanced Liver Disease.International journal of molecular sciences · 2016Article
- The Effect of Renal Function Impairment on the Mortality of Cirrhotic Patients: A Nationwide Population-Based 3-Year Follow-up Study.PloS one · 2016Article
- Renal failure in cirrhosis: Emerging concepts.World journal of hepatology · 2015Review
- Development of a rat model of D-galactosamine/lipopolysaccharide induced hepatorenal syndrome.World journal of gastroenterology · 2015Article
- Acute kidney injury in patients with chronic liver disease.World journal of hepatology · 2015Review
- Neutrophil Gelatinase Associated Lipocalin (NGAL) - a biomarker of renal dysfunction in patients with liver cirrhosis: Do we have enough proof?Journal of medicine and life · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute kidney injury (AKI), defined as an abrupt increase in the serum creatinine level by at least 0.3 mg/dL, occurs in about 20% of patients hospitalized for decompensating liver cirrhosis. Patients with cirrhosis are susceptible to developing AKI because of the progressive vasodilatory state, reduced effective blood volume and stimulation of vasoconstrictor hormones. The most common causes of AKI in cirrhosis are pre-renal azotemia, hepatorenal syndrome and acute tubular necrosis. Differential diagnosis is based on analysis of circumstances of AKI development, natriuresis, urine osmolality, response to withdrawal of diuretics and volume repletion, and rarely on renal biopsy. Chronic glomerulonephritis and obstructive uropathy are rare causes of azotemia in cirrhotic patients. AKI is one of the last events in the natural history of chronic liver disease, therefore, such patients should have an expedited referral for liver transplantation. Hepatorenal syndrome (HRS) is initiated by progressive portal hypertension, and may be prematurely triggered by bacterial infections, nonbacterial systemic inflammatory reactions, excessive diuresis, gastrointestinal hemorrhage, diarrhea or nephrotoxic agents. Each type of renal disease has a specific treatment approach ranging from repletion of the vascular system to renal replacement therapy. The treatment of choice in type 1 hepatorenal syndrome is a combination of vasoconstrictor with albumin infusion, which is effective in about 50% of patients. The second-line treatment of HRS involves a transjugular intrahepatic portosystemic shunt, renal vasoprotection or systems of artificial liver support.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.